Neurofibromatosis type 1 is one of the most common genetic disorders of the nervous
system and predisposes patients to develop benign and malignant tumors. Cutaneous …

This phase 2a trial investigated the efficacy of NFX-179 Topical Gel, a metabolically labile
MEK inhibitor, in the treatment of cutaneous neurofibromas (cNFs) in neurofibromatosis type …

Abstract Background Neurofibromatosis 1 (NF1) is a common cancer predisposition
syndrome. Affected individuals require lifelong surveillance and often suffer progressive …

The skin manifestations of neurofibromatosis 1 significantly reduce health‐related quality‐of‐
life. However, data on the utility of existing surveys in capturing neurofibromatosis 1 skin …

Background Cutaneous neurofibromas (cNF) are considered one of the highest burdens of
neurofibromatosis type 1 (NF1). To date, no medical treatment can cure cNF or prevent their …

Abstract Background Neurofibromatosis type 1 (NF1) is a common inherited disorder
characterized by cutaneous neurofibromas and other features. It is still a challenge in …

Cutaneous neurofibromas (cNF) contribute to the impairment of QOL in individuals with
neurofibromatosis 1. The cNF-Skindex, validated in a French population, specifically …

Abstract Background Neurofibromatosis type 1 (NF1) is one of the most common
RASopathies predisposing affected patients to melanic lesions and benign tumors. NF1 is …

Background: Neurofibromatosis type 1 (NF1) is a genetic disorder that affects multiple
systems in the body, often leading to physical disfigurements and a wide range of clinical …

Importance There is a burgeoning interest in therapeutic development for cutaneous
neurofibromas (cNFs), a major cause of morbidity in persons with neurofibromatosis type 1 …